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Atherosclerosis and abdominal aortic aneurysm (AAA)
are inflammatory diseases that involve extensive extra-
cellular matrix degradation and vascular wall remodel-
ing. Cardiovascular events correlated with the presence
of inflammation and atheroma tend to rupture at sites
of matrix remodeling (1, 2). The exact proteases
involved in these pathological events are currently
unknown. Previous studies have implicated both
matrix metalloproteases (MMPs) (3, 4) and serine pro-
teases (5, 6). Recently, our laboratory isolated 2 potent
elastolytic cysteine proteases, cathepsins S and K (7, 8),
and have demonstrated overexpression of these pro-
teases in atherosclerotic lesions compared with normal
arteries. Macrophages and smooth muscle cells (SMCs)
in atherosclerotic plaques express cathepsins S and K
(9). In the presence of proinflammatory cytokines
found in atheroma, cultured vascular SMCs secrete
active cathepsin S capable of degrading extracellular
elastin (9). Monocyte-derived macrophages also
degrade elastin through release of active cathepsins
(10). Thus, elastolytic and collagenolytic cysteine pro-
teases likely participate in vascular wall remodeling.
By regulating protease activities, protease inhibitors
also play a pivotal role in tissue remodeling (11). The
most abundant extracellular inhibitor of cysteine pro-
teases is cystatin C, a 13-kDa protein constitutively
secreted shortly after its synthesis (12, 13). Cystatin C
belongs to the type 2 cystatin gene family, and clusters
together with other members including cystatins D, S,
SA, and SN on chromosome 20 (14). Cystatins D, S, and
SA are primarily expressed in salivary glands, cystatin C
is expressed in virtually all organs of the body. Owing to
its high concentration in biologic fluids, cystatin C is
probably one of the most important extracellular
inhibitors of cysteine proteases (15–19). Aside from a
rare mutation in cystatin C that leads to its precipita-
tion as amyloid in cerebral blood vessels and causes cere-
bral hemorrhage (20), no evidence thus far has impli-
cated cystatin C in disease. In vitro, alveolar macro-
phages from cigarette smokers or monocytes stimulat-
ed by IFN-g secrete less cystatin C than unstimulated
macrophages or monocytes, raising the possibility of
reduced cystatin C levels at sites of inflammation (21,
22). Whether cystatin C expression actually changes in
situ in diseases in which inflammation is prominent,
and how changes in cystatin C levels might be affected,
are currently unknown.
This study explored the possibility that cystatin C is
deficient in diseased arteries. Normal SMCs highly
express cystatin C, raising the possibility that this
inhibitor could counterbalance augmented cysteine pro-
teases. Surprisingly, initial immunohistochemical analy-
ses of samples from atherosclerotic plaques revealed vir-
tually no cystatin C antigen within plaques. This result
prompted further study of the amounts of cystatin C in
both atherosclerotic plaques and aneurysmal tissues, as
well as measurement of circulating levels of cystatin C in
patients with normal or dilated aortas. We also exam-
ined the regulation of cystatin C expression by vascular
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The pathogenesis of atherosclerosis and abdominal aortic aneurysm involves breakdown of the elas-
tic laminae. Elastolytic cysteine proteases, including cathepsins S and K, are overexpressed at sites of
arterial elastin damage, but whether endogenous local inhibitors counterbalance these proteases is
unknown. We show here that, whereas cystatin C is normally expressed in vascular wall smooth mus-
cle cells (SMCs), this cysteine protease inhibitor is severely reduced in both atherosclerotic and
aneurysmal aortic lesions. Furthermore, increased abdominal aortic diameter among 122 patients
screened by ultrasonography correlated inversely with serum cystatin C levels. In vitro, cytokine-stim-
ulated vascular SMCs secrete cathepsins, whose elastolytic activity could be blocked when cystatin C
secretion was induced by treatment with TGF-b1. The findings highlight a potentially important role
for imbalance between cysteine proteases and cystatin C in arterial wall remodeling and establish that
cystatin C deficiency occurs in vascular disease.
J. Clin. Invest. 104:1191–1197 (1999).SMCs in vitro, as well as the capacity of pericellular cys-
tatin C levels to influence the elastolytic activity of these
cells. The results reveal a previously unsuspected protec-
tive role for cystatin C in vascular remodeling and indi-
cate that a cytokine whose circulating levels are reported
to be depressed in atherosclerosis — TGF-b1 (23) — is a
major inducer of SMC cystatin C secretion.
Methods
Immunohistochemistry. Serial cryostat sections (6 mm) of
human atherosclerotic plaques from coronary (n = 10)
and carotid (n= 6) arteries, aortic aneurysms (n= 6), and
nonatherosclerotic arteries (carotids from autopsies [n=
4] and aortas from cardiac transplantation donors [n =
4]) were fixed in acetone (–20°C, 5 minutes), air-dried,
and stained by an avidin-biotin-peroxidase method as
described previously (9). Tissue sections were treated with
0.3% hydrogen peroxide to inhibit endogenous
peroxidase activity, followed by primary anti-
bodies diluted in PBS supplemented with 4%
species-appropriate normal serum. The subse-
quent processing was performed according to
the manufacturer’s recommendations (Uni-
versal DAKO LSAB kit, peroxidase; DAKO
Corp., Carpinteria, California, USA). The reac-
tion was viewedwith 3-amino-9-ethylcarbazole
(Sigma Chemical Co., St. Louis, Missouri,
USA). Sections were counterstained with Gill’s
hematoxylin solution (Sigma Chemical Co.).
Cell types were identified with monoclonal
anti-muscle actin HHF-35 (Enzo Diagnostics
Inc., Syosset, New York, USA) or monoclonal
anti-human CD68 (macrophages).
Western blot analysis. Frozen atherosclerotic
plaques (n= 7), AAA aortas (n= 4), and normal
arteries (n= 11) were pulverized and lysed into
buffer containing 1% Triton X-100, 40 mM
sodium acetate, and 1 mM EDTA (pH 5.0).
After incubation at 37°C for 1 hour, lysate pro-
tein concentrations were determined using
Bio-Rad Dc Protein Assay kit according to the
manufacturer’s directions (Bio-Rad Laborato-
ries Inc., Hercules, California, USA). Thirty
micrograms of protein from each sample was
separated on SDS-PAGE, blotted onto nitro-
cellulose filter, and probed with rabbit anti-
human cystatin C (1:1,000; DAKO Corp.) or
human cathepsin S (1:1,000).
Human saphenous vein SMCs were cul-
tured in a 6-well plate in DMEM containing
10% FBS until confluent. Cells were then cul-
tured in serum-free DMEM for 24 hours, fol-
lowed by stimulation with IFN-g (500 U/mL)
for an additional 24 hours in the presence or
absence of 10 ng/mL TGF-b1. Culture medi-
um was then collected and centrifuged at
16,000 g for 10 minutes. Proteins were pre-
cipitated with 20% trichloroacetic acid on ice
for 30 minutes followed by repeat centrifugation. The
protein pellet was briefly washed with 100% ethanol
and resuspended in electrophoresis sample buffer.
SMCs were lysed directly into sample buffer after 2
washes with 1´PBS. Both cell lysates and proteins from
culture medium were separated on SDS-PAGE for
immunoblot analysis with antibodies against human
cathepsin S and cystatin C as already described here. All
Western blots were developed with Western Blot
Chemiluminescence Reagent (NEN Life Science Prod-
ucts Inc., Boston, Massachusetts, USA). 
Northern blot analysis. After IFN-g and TGF-b1 treat-
ments, 1.5 ´ 107 SMCs were lysed in 5 mL of guanidi-
um isothiocyanate lysis buffer for RNA preparation as
described elsewhere (9). Twenty micrograms of total
RNA from SMCs was separated on 1.2% agarose gel
and blotted on Zeta-Probe GT blotting membrane
(Bio-Rad Laboratories Inc.). A human cystatin C probe
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Figure 1
Decreased expression of cystatin C in atherosclerotic plaques and AAAs. Frozen
sections of normal arteries (´100) (a), atherosclerotic plaques (´20) (b–d), fatty
streaks (n = 4; ´40) (e–g), and AAAs (´100) (h) were used for immunohisto-
chemistry with rabbit anti–cystatin C polyclonal antibodies (a, b, e, and h). The
distribution of SMCs and macrophages within the lesions was determined by cel-
lular staining with a-actin (c and f) and CD68 mAb’s (d and g), respectively.was generated by PCR using cystatin C cDNA (a kind
gift from M. Abrahamson, University of Lund, Lund,
Sweden). The 500-bp cystatin C cDNA fragment and
cathepsin S cDNA probe (9) were labeled with
[32P]dCTP and purified with NENSORB 20 column
(NEN Life Science Products Inc.) before hybridizing as
described elsewhere (9).
Elastase assay. SMCs were cultured on 24-well plates in
10% FBS DMEM until 100% confluence (5 ´ 105 cells
per well). Cells were then cultured in serum-free DMEM
for 24 hours before stimulation with IFN-g(500 U/mL)
and/or TGF-b1 (1–25 ng/mL). Bovine neck ligament
elastins (Elastin Products Inc., Pacific, Missouri, USA)
were tritiated with [3H]sodium borohydride (NEN Life
Science Products Inc.) as described previously (24). Both
stimulated and nonstimulated SMCs were incubated
with 300 mg [3H]elastin (1,300 cpm/mg) for 3 days at
37°C. The inhibitory effect of cystatin C was examined
by incubating SMCs with recombinant cystatin C
(0–500 ng/mL) or rabbit anti-human cystatin C IgG
(100 mg/mL; Cortex Biochem, San Leandro, California,
USA). Culture media were then collected by centrifuga-
tion at 16,000 g for 15 minutes. The digested elastin
radioactivity was counted using 200 mL of medium, and
the data were presented as micrograms of elastin
degraded per 106cells in 24 hours.
Patient population and ELISA. Outpatients older than 50
years of age, referred to the Noninvasive Cardiac Labo-
ratory of the Brigham and Women’s Hospital for a
transthoracic echocardiogram, were invited to partici-
pate in a study examining markers of vascular disease
(25, 26). Patients with a clinical history consistent with
active infection, systemic inflammatory disease, or heart
transplant and those taking corticosteroids were exclud-
ed. Overall, 122 eligible patients agreed to participate
and constituted the study population. Ultrasound eval-
uations were performed by 2 experienced ultrasonogra-
phers, using commercially available equipment
(Hewlett Packard Sonos 2500; Hewlett Packard Medical
Products, Andover, Massachusetts, USA) and a 2.7/3.5
MHz phase-array transducer (for the aorta) or a 5.5/7.0
MHz linear transducer (for the carotid imaging) as
described elsewhere (26). Before the imaging proce-
dures, individual data concerning atherosclerosis risk
factors, prior cardiovascular history, and other comor-
bidities were obtained. The protocol was reviewed and
approved by the Human Research Committee of the
Brigham and Women’s Hospital, and informed consent
was obtained for all patients. Among these subjects, 8
patients were identified with abdominal aortic dilata-
tion as defined with periumbilical aorta diameter larg-
er than 2.5 cm. Serum samples from all patients were
collected and used for cystatin C ELISA as described
elsewhere (17–19). Briefly, 96-well immunosorb plates
(NUNC Co., Naperville, Illinois, USA)were coated with
cystatin C polyclonal IgG (10 mg/mL; Cortex Biochem)
in NaHCO3 (pH 8.2) overnight at 4°C. After wash and
3% BSA blocking, plates were incubated with diluted
human serum samples and were again incubated
overnight at 4°C. Cystatin C mAb’s (1 mg/mL) were
used as detecting antibody followed with peroxidase-
conjugated goat anti-mouse IgG/IgM (1:1,000;
Kirkegaard & Perry Laboratories, Gaithersburg, Mary-
land, USA). ELISA plates were developed with OPD
(Sigma Chemical Co.). Recombinant cystatin C was
used as standard of each plate.
Results
Immunostaining of normal vessels and atherosclerotic
plaques. Atherosclerotic plaques overexpress elastolyt-
ic cathepsins S and K (9). To examine whether the
lesions also exhibit altered levels of their endogenous
inhibitor cystatin C, both plaques and normal vessels
were immunostained with rabbit anti-human cystatin
C polyclonal antibodies. Normal arteries had abun-
dant cystatin C staining (n = 6) (Figure 1a). However,
atherosclerotic plaques (n = 10) showed little
immunoreactive cystatin C (Figure 1b). Macrophages
and SMCs in the developing plaques were identified by
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Figure 2
Immunoblotting of normal arteries, atherosclerotic plaques, and aor-
tic aneurysms. Equivalent total protein from detergent extracts of nor-
mal arteries (n= 11), atherosclerotic plaques (n= 7), and AAAs (n= 4)
was separated on SDS-PAGE and immunoblotted with rabbit poly-
clonal antibodies against cystatin C or cathepsins S and K as indicat-
ed in the figure. Both atherosclerotic plaques (a) and aortic aneurysms
(b) demonstrated markedly decreased cystatin C antigen, whereas
both cathepsins S and K were increased in aneurysmal aortas (b).immunostaining plaques with mouse anti-human
CD68 (macrophage-specific) and mouse anti-human
a-actin (SMC-specific) antibodies. As expected, vivid
CD68 staining was found at the lipid core and shoul-
der areas of the plaque (Figure 1d), whereas a-actin
staining was found mostly in the fibrous cap (Figure
1c). The specificity of immunohistochemistry was con-
firmed using nonimmune rabbit serum (data not
shown). Interestingly, the level of cystatin C in athero-
sclerotic plaques appeared to correlate inversely with
disease progression. Early stages of plaque develop-
ment (fatty streaks; n = 4) showed very little immun-
odetectable cystatin C, whereas SMC of underlying
media (a-actin positive; Figure 1f) demonstrated
stronger staining for cystatin C (Figure 1e). AAAs (n =
6) displayed a similar lack of cystatin C staining (Fig-
ure 1h) as well as increased cathepsin S immunostain-
ing (data not shown). Thus, AAAs and atherosclerotic
plaques contain scant cystatin C.
To explore biochemically the apparent cystatin C
deficiency in these lesions, protein extracts of athero-
sclerotic artery (n = 7), aneurysmal tissue (n = 4), and
normal control vessel (n = 11) were examined by
immunoblotting with cathepsin and cystatin C anti-
bodies. Similar to the findings with immunostaining
(Figure 1), the immunoblot analysis with cystatin C
antibodies showed a dramatic decrease of 13-kDa cys-
tatin C antigen in atherosclerotic plaque extracts (Fig-
ure 2a) and AAA extracts (Figure 2b) compared with
normal arteries. As expected, cathepsin S and K expres-
sion (Figure 2b) in AAA extracts was increased, consis-
tent with previously reported data for atherosclerotic
plaques (9). These findings provide further evidence for
a disturbed balance between proteases and antipro-
teases involving elastolytic and collagenolytic cysteine
proteases in these diseased vessel walls.
Correlation between AAA aorta diameter and serum cys-
tatin C levels. On the basis of evidence detailed here indi-
cating a deficiency of cystatin C in aneurysmal aortic
tissue, we explored the possibility that circulating lev-
els of cystatin C may relate to the development of AAAs.
A cohort of patients (n= 122) referred to an outpatient
cardiology clinic for echocardiographic testing under-
went measurements of carotid artery intimal to medi-
al thickness (IMT) ratios and aortic diameter. Correla-
tions between these measurements and circulating
indices of inflammation in this cohort have been pub-
lished previously (25, 26). We measured the serum cys-
tatin C levels in these patients using a cystatin C ELISA.
This method has been previously used to quantify cys-
tatin C levels in human gingiva (17), cerebrospinal
fluid (18), and normal serum (19). The serum cystatin
C levels were quantitated against a recombinant cys-
tatin C standard. No significant correlation between
IMT and cystatin C levels was apparent. However, a sig-
nificant negative correlation of abdominal aortic diam-
eters with serum cystatin C levels was observed (P <
0.03; r = 0.203). The correlation remained significant
when aortic diameter was corrected for body surface
area and when cystatin C was normalized to serum cre-
atinine, glomerular filtration being a known determi-
nant of cystatin C levels (27) (not shown). Although the
number of patients with frankly dilated aortas (> 2.5
cm) is small (n= 8), all patients with dilated aortas had
relatively low circulating cystatin C (0.516 ± 0.233
mg/mL; mean ± SD, Mann-Whitney) (Figure 3). As a
group, these subjects had significantly lower serum cys-
tatin C levels than that of subjects with aortic diame-
ters less than 2.5 cm (1.303 ±1.064 mg/mL; mean ±SD;
P < 0.03) (Figure 3). There was no significant associa-
tion of cystatin C with age, race, sex, history of smok-
ing, diabetes, myocardial infarction, revascularization,
or lipoprotein levels. Thus, these findings concur with
biochemical evidence indicating that a disruption in
the balance between cysteine protease expression and
cystatin C levels may play a role in vascular remodeling.
Cystatin C expression and regulation of vascular SMC elas-
tolytic activity. Prior studies documenting the capacity of
macrophages to use cysteine proteases to degrade elastin
found macrophage elastolytic activity to be insensitive
to the presence of pericellular serum protease inhibitors
(10, 28). These findings raise questions as to whether, in
spite of the marked reduction of cystatin C in athero-
sclerotic and aneurysmal lesions and the clinical corre-
lation (Figures 1–3), cystatin C can actually regulate ves-
sel wall matrix remodeling by vascular cells. To address
this uncertainty, the influence of cystatin C on the elas-
tolytic activity of cultured vascular SMCs was examined.
Vascular SMCs were stimulated with IFN-g(500 U/mL)
for 24 hours to augment cathepsin S–dependent elas-
tase activity (9). In subsequent cocultures with insoluble
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Figure 3
Comparison of serum cystatin C levels between patients with dilated
(diameter > 2.5 cm) and normal aorta (diameter < 2.5 cm). A cohort
of outpatients (n = 122) underwent ultrasound measurements of
their abdominal aortas. Patients with dilated aorta (n = 8) had lower
serum cystatin C (0.516 ± 0.233 mg/mL; mean ± SD) than patients
with normal aorta (n = 114) (1.303 ± 1.064 mg/mL; mean ± SD; P <
0.03, Mann-Whitney). The aortic diameters of all subjects were
inversely correlated with serum cystatin C levels (P < 0.03; r = 0.203;
simple regression analysis) in blood drawn at the time of the outpa-
tient visit. A similar correlation (P < 0.04) was observed with indexed
aortic diameter (diameter/body surface area) or with aortic diame-
ter as a function of cystatin C corrected for serum creatinine, a
known determinant of cystatin C levels (data not shown).elastin, the addition of as little as 10 ng/mL of recombi-
nant cystatin C inhibited elastin degradation (Figure
4a). Higher concentrations of cystatin C blocked more
than 75% of the IFN-g–induced activity, confirming that
SMC elastase activity depends largely on elastolytic cys-
teine proteases.
Given that normal medial SMCs express cystatin C
(Figure 1), we next examined the regulation of cystatin
C secretion by cultured SMCs. Total RNAs were isolat-
ed from control and IFN-g-stimulated SMCs for
Northern blot analysis. As expected, cathepsin S mRNA
was markedly increased in stimulated cells compared
with controls. However, the level of cystatin C mRNA
was unchanged (Figure 4b), consistent with the consti-
tutive nature of the cystatin C promoter (29). To
explore further the regulation of cystatin C expression
in SMC, we also tested a cytokine previously reported
to induce other classes of protease inhibitors, TGF-b1
(30–32). TGF-b1 (5 ng/mL) did not change the level of
cathepsin S mRNA or protein or of cystatin C mRNA
(Figure 4b). However, TGF-b1 markedly increased the
level of secreted cystatin C (Figure 4c, top panel). Addi-
tional experiments indicate that cystatin C biosynthe-
sis increases as little as 1 hour after exposure of SMCs
to TGF-b1 (not shown). Consistent with this observa-
tion, as little as 1 ng/mL of recombinant TGF-b1
almost completely blocked the elastase activity of IFN-
g-stimulated SMCs (Figure 4d). To test further the link
between the elastase “protective” effect of TGF-b1 and
increased cystatin C secretion, INF-g–induced SMCs
from 2 individuals were cultured with 10 ng/mL of
TGF-b1 and 100 mg/mL of rabbit anti-human cystatin
C IgG (Cortex Biochem) or normal rabbit IgG (Sigma
Chemical Co.). Addition of cystatin C antibodies com-
pletely restored the elastase activity induced by IFN-g
in the presence of TGF-b1 (9.803 ± 2.79 mg elastin
degraded per 106cells per 24 hours; mean ±SD) to that
of SMCs stimulated by IFN-g alone (10.00 ± 3.4). In
contrast, the control IgG had no effect on elastin
degradation by either cytokine-stimulated or unstim-
ulated SMCs. Thus, cytokine-induced SMC elastase
activity depends on pericellular cystatin C levels, and
TGF-b1can inhibit elastin degradation by induction of
cystatin C secretion.
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Figure 4
Regulation of SMCs elastase activity by cystatin C. (a) SMC elastase activity is inhibited by recombinant cystatin C. Interferon-g stimulated
SMCs were cocultured in serum-free medium with insoluble elastin in the presence of increasing concentrations of cystatin C as indicated
in the panel. After 72 hours, media were collected and soluble radioactivity measured as an index of elastin degradation. (b) TGF-b1 does
not alter cystatin C and cathepsin S mRNA levels. Northern blot analysis of SMC stimulated with IFN-g (500 U/mL) or TGF-b1 (10 ng/mL)
for 24 hours. (c) TGF-b1 stimulates SMC cystatin C secretion. Cells were stimulated with TGF-b1 as described in the text and media collect-
ed for immunoblots after 24 hours. As previously reported (9), IFN-g induced cathepsin S mRNA (b) and secretion of active cathepsin S (c)
but had no effect on cystatin C secretion. (d) TGF-b1 blocks SMC elastase activity. IFN-stimulated SMCs were cocultured with elastin as
described in the text in the presence of increasing amounts of TGF-b1 and elastin degradation quantified after 72 hours.Discussion
Imbalance of proteolytic and antiproteolytic levels may
result in lung destruction (33, 34), tumor progression
(35, 36), and possibly vascular wall remodeling (37–41).
Several lines of evidence reported in this study indicate
that the severely depressed levels of cystatin C found in
lesions of patients with atherosclerosis and aortic
aneurysms contribute to progression of vascular injury.
First, cysteine proteases with potent elastase and colla-
genase activities are markedly elevated at sites of elastin
and collagen degradation, both in advanced plaques in
vascular arteries susceptible to rupture and in
aneurysms of the aorta, a large elastic vessel where there
is massive elastin breakdown (ref. 9; Figure 2). Second,
IFN-g-stimulated SMCs secrete an elastolytic cathep-
sin, cathepsin S, and IFN-g is present within diseased
arteries (42, 43), providing a basis for cysteine proteas-
es to overwhelm residual pericellular cystatin C. Third,
we observed a significant inverse correlation between
blood cystatin C levels and aortic dilatation, consistent
with a protective effect of cystatin C on matrix break-
down (Figure 3). And finally, a cytokine identified in
this study as a major inducer of SMC cystatin C secre-
tion, TGF-b1(Figure 4), is reportedly severely depressed
in plasma of patients with atherosclerosis (23). Taken
together, these findings indicate that deficiency of cys-
tatin C likely contributes to progression of vascular
remodeling and, by inference, that elastolytic cysteine
proteases are also important contributors to the
pathophysiology of these diseases.
The severe depression of cystatin C antigen levels
within SMCs of atherosclerotic plaques implies a
marked change in the functional properties of plaque
SMC. Normal medial SMCs express abundant cystatin
C (Figure 1). Such changes in the phenotypic proper-
ties of these SMCs are consistent with other evidence
that migrating vascular SMCs have protease and pro-
tease inhibitor profiles distinctly different from resi-
dent cells of the vessel wall. SMCs in atheromatous
arteries have augmented MMP levels (44, 45).
Macrophages within atherosclerotic and aneurysmal
tissues also exhibit increased expression of MMPs (46,
47). However, in contrast to results reported here for
cystatin C, tissue inhibitors of matrix metallopro-
teinases (TIMPs) have been found to be either
unchanged or overexpressed in both atherosclerotic
lesions (38, 39) and AAAs (48, 49). Inflammatory
cytokines and growth factors increase the expression of
TIMP-1 and TIMP-3 in atherosclerotic lesion–related
macrophages and vascular SMCs (38).
To our knowledge, the marked suppression of cystatin
C concurrent with augmented expression of cysteine
proteases observed in our studies of atherosclerosis and
abdominal aneurysms represents the first acquired cys-
teine protease inhibitor deficiency in human disease.
Our findings of a significant inverse correlation
between cystatin C levels and distal aortic diameters (Fig-
ure 3) must be viewed as preliminary. Only a small frac-
tion (n= 8) of the screened subjects had distinctly dilat-
ed aortas. Most subjects also had normal carotid intimal
thickness. None of these outpatients had severe wall
thickening of the common carotid (> 2 mm IMT), and
only 6 patients had larger than 2 mm of carotid bifurca-
tion IMT. This may explain the relatively low correlation
coefficient (r = 0.203) relating aortic diameter to circu-
lating cystatin C levels. Cystatin C levels likely have little
influence on variation in aortic dimensions among nor-
mal subjects. Rather, our data suggest that cystatin C lev-
els contribute to progression of vascular remodeling,
consistent with significantly lower cystatin C levels
among subjects with dilated aortas (Figure 3). Addition-
al studies of more severely affected populations will be
needed to test the relationship revealed in our studies.
We also think it is unlikely that alterations in the cir-
culating levels of cystatin C contribute to the severe
depression of lesional cystatin C observed in injured ves-
sel walls. Rather, the downward skewing of circulating
cystatin C levels among subjects with dilated aortas, and
the severe depletion of cystatin C within atherosclerotic
and aneurysmal lesions, likely indicate a common
response to similar local and systemic changes in the
cytokine milieu in these settings. Numerous studies have
documented evidence of increased local and systemic
markers of inflammation, e.g., the cytokine IL-6 and the
acute-phase reactant, C-reactive protein, in atheroscle-
rosis and aneurysmal disease (43, 50). In addition, both
decreased systemic active TGF-b1and local resistance to
TGF-b1 activity have been reported in atherosclerosis
(23, 51). Low TGF-b1 activity could explain the low lev-
els of lesional cystatin C and, potentially, the inverse cor-
relation with aortic dilatation observed in this study,
because we found TGF-b1 to be a potent inducer of cys-
tatin C secretion by vascular SMCs (Figure 4c). Reversal
of TGF-b1–mediated elastase inhibition by cystatin C
antibodies confirms that induction of cystatin C secre-
tion underlies the protective effect of TGF-b1on elastin
degradation. Thus, our results indicate an additional
mechanism by which TGF-b1 deficiency could con-
tribute to the pathophysiology of vascular wall remod-
eling and atherogenesis. The restoration of a physiolog-
ical balance between the elastolytic cathepsins and
inhibitors of these proteases merits study as a novel ther-
apeutic strategy, especially in aneurysmal disease in
which matrix breakdown is dramatic.
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